Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction

被引:30
作者
Miller, Chadwick D.
Roe, Matthew T.
Mulgund, Jyotsna
Hoekstra, James W.
Santos, Renato
Pollack, Charles V.
Ohman, Magnus
Gibler, Brian
Peterson, Eric D.
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA
[2] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[3] Univ Penn, Sch Med, Penn Hosp, Philadelphia, PA 19104 USA
[4] Univ Cincinnati, Coll Med, Cincinnati, OH USA
关键词
acute coronary syndromes; beta blockers; guidelines; patient care;
D O I
10.1016/j.amjmed.2007.04.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: Early use of beta-blockers is a quality indicator for the treatment of patients with non -STsegment elevation myocardial infarction (NSTEMI), despite limited data from randomized clinical trials in this population. We sought to determine the impact of acute beta-blocker therapy on outcomes in patients with NSTEMI. SUBJECTS AND METHODS: We examined acute (< 24 hours) beta-blocker use in 72,054 patients with NSTEMI from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) initiative at 509 US hospitals from 2001-2004. We analyzed patient and provider factors associated with beta-blocker use and the impact of beta-blocker therapy on unadjusted, risk-adjusted, and propensity matched outcomes in the overall sample and among selected high-risk subgroups. RESULTS: A total of 82.5% of patients without documented contraindications received acute beta-blocker therapy. Factors strongly associated with acute beta-blocker use included prior beta-blocker use, higher presenting systolic blood pressure, lower heart rate, lack of signs of heart failure, and cardiology care. Acute beta-blocker use was associated with lower in-hospital mortality (unadjusted 3.9% vs 6.9%, P <. 001, adjusted odds ratio 0.66, 95% confidence interval 0.60-0.72), lower adjusted mortality among most of 6 subgroups determined by propensity to receive acute beta-blockers, and lower adjusted mortality in patients with and without signs of heart failure and in those < 80 years and those >= 80 years old. CONCLUSIONS: The majority of NSTEMI patients receive acute beta-blocker therapy. Certain patient subgroups remain undertreated. Because treatment with acute beta-blockers was associated with improved clinical outcomes in nearly all patient subgroups assessed, broader use in patients with NSTEMI appears warranted. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:685 / 692
页数:8
相关论文
共 19 条
[1]  
[Anonymous], 1986, Lancet, V2, P57
[2]   A qualitative study of increasing β-blocker use after myocardial infarction -: Why do some hospitals succeed? [J].
Bradley, EH ;
Holmboe, ES ;
Mattera, JA ;
Roumanis, SA ;
Radford, MJ ;
Krumholz, HM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (20) :2604-2611
[3]   ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (07) :1366-1374
[4]   Are β-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? [J].
Chen, J ;
Radford, MJ ;
Wang, Y ;
Marciniak, TA ;
Krumholz, HM .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :947-952
[5]  
Chen ZM, 2005, LANCET, V366, P1622
[6]   Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J].
Dargie, HJ ;
Colucci, Y ;
Ford, I ;
Sendon, JLL ;
Remme, W ;
Sharpe, N ;
Blank, A ;
Holcslaw, TL .
LANCET, 2001, 357 (9266) :1385-1390
[7]   MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION IN THE VERY ELDERLY [J].
FORMAN, DE ;
BERNAL, JLG ;
WEI, JY .
AMERICAN JOURNAL OF MEDICINE, 1992, 93 (03) :315-326
[8]   Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction [J].
Gottlieb, SS ;
McCarter, RJ ;
Vogel, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (08) :489-497
[9]  
HJALMARSON A, 1985, EUR HEART J, V6, P199
[10]   Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure -: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) [J].
Hjalmarson, Å ;
Goldstein, S ;
Fagerberg, B ;
Wedel, H ;
Waagstein, F ;
Kjekshus, J ;
Wikstrand, J ;
El Allaf, D ;
Vítovec, J ;
Aldershvile, J ;
Halinen, M ;
Dietz, R ;
Neuhaus, KL ;
Jánosi, A ;
Thorgeirsson, G ;
Dunselman, PHJM ;
Gullestad, L ;
Kuch, J ;
Herlitz, J ;
Rickenbacher, P ;
Ball, S ;
Gottlieb, S ;
Deedwania, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (10) :1295-1302